PROLOR Biotech to Present at Jefferies 2011 Global Healthcare Conference

NES-ZIONA, Israel, Sept. 21, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Jefferies 2011 Global Healthcare Conference on September 27, 2011 at 8:00 AM BST.  The conference is being held September 27-28, 2011 at the Waldorf Hilton Hotel in London, United Kingdom.

For more information on the Jefferies 2011 Global Healthcare conference, visit: http://www.jefferies.com/cositemgr.pl/html/OurFirm/ConferencesEvents/upcoming/20110927GlobalHealth.shtml, or email [email protected].

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is completing Phase II clinical development, as well as Factor VII, Factor IX, interferon beta, erythropoietin, an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development.  For more information, visit www.prolor-biotech.com.

PROLOR CONTACT:

MEDIA CONTACT:

Shai Novik, President

Barbara Lindheim

PROLOR Biotech, Inc.

GendeLLindheim BioCom Partners

Tel: +1 866 644-7811

+1 212 918-4650

Email: [email protected]

[email protected]



SOURCE PROLOR Biotech, Inc.

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.